
    
      The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been
      renamed to Bayer Schering Pharma AG, Germany.

      Bayer Schering Pharma AG, Germany is the sponsor of the trial.

      Although the title of the study describes "open", it was in fact single-blinded.

      Issues on side effects are addressed in the Adverse Event section.
    
  